Special Issue "Advances in Vaccinal Control of COVID-19"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 13235
Vaccine deployment for SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic, represented an extraordinary feat of biomedical innovation. Multiple vaccines have been developed, and 12 billion doses administered worldwide. However, despite this herculean effort, the pandemic continues to rage. Vaccinal (and natural) immunity wane quickly for SARS-CoV-2, making herd immunity infeasible. High levels of ongoing viral transmission and rapid viral evolution have led to repeated waves of disease, posing the risk of the emergence of more virulent variants of SARS-CoV-2. Thus, effective vaccines—capable of suppressing transmission and robust to viral evolution—remain an unmet need. Much work also remains to be carried out to find optimal vaccination strategies that are equitable and effective at suppressing disease spread.
This Special Issue will focus on novel research reports, reviews, and methodologies examining current and novel vaccines and vaccination strategies, from a biomedical research or public health perspective. Studies may include (but are not limited to): model-based analyses of SARS-CoV-2 vaccine performance or control strategies (e.g., using pharmacokinetic, epidemiological or evolutionary modeling), studies characterizing determinants of vaccine performance (e.g., immunological correlates, mucosal response), immunoinformatics or in silico studies for vaccine design, and preclinical/clinical studies characterizing vaccines (e.g., in vitro assays, immunogenicity or efficacy studies) currently in development.
Dr. Arijit Chakravarty
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- COVID-19, SARS-CoV-2
- vaccine development
- viral evolution
- public health